Literature DB >> 24104958

Human parechovirus central nervous system infections in southern California children.

Susanna Felsenstein1, Shangxin Yang, Natalie Eubanks, Edwin Sobrera, John P Grimm, Grace Aldrovandi.   

Abstract

BACKGROUND: Human parechoviruses (hPeV) are increasingly recognized as significant etiological agents for meningoencephalitis especially in young children, but testing of cerebrospinal fluid (CSF) for hPeV by PCR is not routinely performed.
METHODS: We used real-time reverse transcriptase PCR for detection of serotypes 1-6 in CSF samples of 440 children who underwent a lumbar puncture to exclude an infectious etiology of their clinical presentation. We then compared the prevalence and clinical presentation of children with hPeV-positive CSF with that of children with enterovirus (EV)-positive CSF.
RESULTS: HPeV was detected in 2.7% and EV in 10.7% of CSF samples. Many hPeV-positive patients were <3 months of age and usually had CSF parameters within the age-adjusted normal range. However, children with hPeV-positive CSF presented with neurologic symptoms more frequently than those with EV-positive CSF.
CONCLUSIONS: HPeV infections of the central nervous system occurred mainly in young infants and were more commonly associated with neurologic symptoms at presentation, despite the fact that CSF findings were within the normal range in the vast majority of these cases. HPeV should be included in the differential diagnosis of young children with central nervous system symptoms and sepsis-like illness, even in the presence of normal CSF parameters.

Entities:  

Mesh:

Year:  2014        PMID: 24104958     DOI: 10.1097/INF.0000000000000112

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  8 in total

Review 1.  Human Parechovirus: an Increasingly Recognized Cause of Sepsis-Like Illness in Young Infants.

Authors:  Laudi Olijve; Lance Jennings; Tony Walls
Journal:  Clin Microbiol Rev       Date:  2017-11-15       Impact factor: 26.132

2.  Antifungal Triazole Posaconazole Targets an Early Stage of the Parechovirus A3 Life Cycle.

Authors:  Eric Rhoden; Terry Fei Fan Ng; Ray Campagnoli; W Allan Nix; Jennifer Konopka-Anstadt; Rangaraj Selvarangan; Laurence Briesach; M Steven Oberste; William C Weldon
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

3.  One Year in the Life of a Rapid Syndromic Panel for Meningitis/Encephalitis: a Pediatric Tertiary Care Facility's Experience.

Authors:  Samia N Naccache; Maryann Lustestica; Margil Fahit; Javier Mestas; Jennifer Dien Bard
Journal:  J Clin Microbiol       Date:  2018-04-25       Impact factor: 5.948

4.  Intracranial hemorrhage and other symptoms in infants associated with human parechovirus in Vienna, Austria.

Authors:  Herbert Kurz; Ruth Prammer; Wolfgang Bock; Robert Ollerieth; Günther Bernert; Karl Zwiauer; Judith H Aberle; Stephan W Aberle; Tamas Fazekas; Wolfgang Holter
Journal:  Eur J Pediatr       Date:  2015-06-25       Impact factor: 3.860

5.  Novel Presentation of Parechovirus Encephalitis in Children: Two Unique Cases.

Authors:  Trupti Pandit; Ramesh Pandit; Lokesh Goyal; Kunal Ajmera; Naresh Dasari
Journal:  Cureus       Date:  2022-06-30

6.  Seropositivity and epidemiology of human parechovirus types 1, 3, and 6 in Japan.

Authors:  K Watanabe; C Hirokawa; T Tazawa
Journal:  Epidemiol Infect       Date:  2016-08-30       Impact factor: 4.434

7.  Antifungal azoles itraconazole and posaconazole exhibit potent in vitro antiviral activity against clinical isolates of parechovirus A3 (Picornaviridae).

Authors:  Eric Rhoden; W Allan Nix; William C Weldon; Rangaraj Selvarangan
Journal:  Antiviral Res       Date:  2017-11-15       Impact factor: 10.103

8.  The particulars on parechovirus.

Authors:  Gauri Shah; Joan L Robinson
Journal:  Can J Infect Dis Med Microbiol       Date:  2014-07       Impact factor: 2.471

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.